INLURIYO imlunestrant
Drug Class
Oral selective estrogen receptor degrader (SERD)口服选择性雌酮受体降解剂 (SERD)
Mechanism
Binds selectively to estrogen receptor alpha (ER-alpha) and promotes its degradation, inhibiting estrogen-dependent gene transcription and tumor growth.特异性结合雌激素受体alpha (ER-alpha) 并促进其降解，阻断雌激素信号传导，从而抑制肿瘤细胞的生长。
Approved Indication
FDA-approved for adult patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after endocrine therapy.FDA批准用于治疗在接受内分泌治疗后病情进展的、雌受体（ER）阳性、HER2阴性、且伴有ESR1突变的晚期或转移性乳腺癌成人患者。
What This Means For Patients
INLURIYO is an oral selective estrogen receptor degrader (SERD) for hormone receptor-positive advanced breast cancers with ESR1 mutations. It is approved by the FDA and available in Boao Lecheng.INLURIYO 是一种口服选择性雌激素受体降解剂（SERD），专门用于治疗伴有ESR1突变的激素受体阳性晚期乳腺癌。其已获FDA批准，并可在博鳌乐城申请临床特许使用。
Regulatory Approvals
- FDA — approved (2025) — source
Pivotal Clinical Evidence
- EMBER-3 — Goetz et al., N Engl J Med 2024 (NCT04625257) — DOI
Sources
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.